DTech Liquidating

DTech Liquidating Payables Turnover

Delisted

The Payables Turnover Ratio of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 10.12. In the previous year, Payables Turnover Ratio was 5.78 — a change of 75.13% (higher).

Payables Turnover

10.12

YoY

75.13%

Last updated:

Payables Turnover Ratio of DTech Liquidating is 2023 10.12 . Payables Turnover Ratio of DTech Liquidating was 2022 5.78 . It decreases by 75.13% higher compared to the previous year.

The DTech Liquidating Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2019
2.06 USD
Jan 1, 2020
3.74 USD
Jan 1, 2021
3.64 USD
Jan 1, 2022
5.78 USD
Jan 1, 2023
10.12 USD
The DTech Liquidating Payables Turnover history
YEARPayables TurnoverYoY
10.12+75.13%
5.78+58.71%
3.64-2.57%
3.74+81.21%
2.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Payables Turnover Ratio of DTech Liquidating is 10.12 in 2023.

Payables Turnover Ratio of DTech Liquidating changed from 5.78 to 10.12, representing a 75.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — DTech Liquidating

All Key Metrics — DTech Liquidating